Article Versions Notes

Mouri A, Watanabe S, Tokito T, Nagai Y, Saida Y, Imai H, Yamaguchi O, Kobayashi K, Kaira K, Kagamu H. Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab. Cancers. 2024; 16(7):1409. https://doi.org/10.3390/cancers16071409

Mouri, Atsuto, Satoshi Watanabe, Takaaki Tokito, Yoshiaki Nagai, Yu Saida, Hisao Imai, Ou Yamaguchi, Kunihiko Kobayashi, Kyoichi Kaira, and Hiroshi Kagamu. 2024. "Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab" Cancers 16, no. 7: 1409. https://doi.org/10.3390/cancers16071409

Mouri, A., Watanabe, S., Tokito, T., Nagai, Y., Saida, Y., Imai, H., Yamaguchi, O., Kobayashi, K., Kaira, K., & Kagamu, H. (2024). Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab. Cancers, 16(7), 1409. https://doi.org/10.3390/cancers16071409